Search

C26H38N2S4Sn, triclinic, P1‾ $P\overline{1}$ (no. 2), a = 9.6272(1) Å, b = 12.1043(2) Å, c = 13.3584(2) Å, α = 82.296(1)°, β = 86.611(1)°, γ = 66.912(1)°, V = 1419.02(4) Å3, Z = 2, Rgt (F) = 0.0235, wR ref(F 2) = 0.0612, T = 100 K.

The process of development and optimization of anticancer drugs entails the design, synthesis, and elucidating of a diverse range of compounds. Among these are organotin(IV) dithiocarbamate metal complexes, which offer promising potential as anti-cancer agents. Recent studies have underscored the potential of these complexes to exert encouraging anti-proliferative activities against cancer cells, which can be attributed to their distinctive molecular structures and interactions with malignant tissues. This study aimed to refine the chemical constitution of Ph2Sn (N-ethyl-N-benzyldithiocarbamate) through the application of cutting-edge analytical methods, including elemental and spectral analysis (infrared (IR) and NMR spectroscopy). Following optimization, the bioactivity of the newly designed compounds was evaluated on A549 human lung cancer cells utilizing standardized MTT assays to bring a better understanding of the structureactivity relationship (SAR). Our results indicate that these compounds display augmented cytotoxicity vis-à-vis current platinum-based chemotherapeutics, cisplatin, thereby highlighting their potential as an innovative alternative to conventional anti-cancer therapies. [ABSTRACT FROM AUTHOR]

C26H38N2S4Sn, triclinic, P 1 ‾ (no. 2), a = 9.6272(1) Å, b = 12.1043(2) Å, c = 13.3584(2) Å, α = 82.296(1)°, β = 86.611(1)°, γ = 66.912(1)°, V = 1419.02(4) Å3, Z = 2, Rgt(F) = 0.0235, wRref(F2) = 0.0612, T = 100 K. [ABSTRACT FROM AUTHOR]